期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌组织中肿瘤转移相关基因1和基质金属蛋白酶的表达及其临床意义 被引量：1

Expression of metastasis-associated gene 1 and MMP-9 in breast carcinoma and its significance
原文传递
导出
摘要 目的研究乳腺癌组织中肿瘤转移相关基因1（MTA1）蛋白和基质金属蛋白酶-9（MMP-9）的表达及其与临床病理资料之间的关系。方法应用免疫组化SP法检测56例乳腺癌组织中MTA1、MMP-9蛋白的表达。结果56例乳腺癌组织中39例MTA1蛋白阳性表达（69．6％），41例MMP-9蛋白阳性表达（73．2％），MTA1和MMP-9的高表达与乳腺癌组织学分级、临床分期和淋巴结转移关系密切（均P〈0．05）。结论MTA1和MMP-9蛋白的表达可以作为判断乳腺癌预后及术后综合治疗的生物学指标。 Objective To investigate the expression of metastasis-associated gene 1 （MTA1 ） and MMP-9 gene in breast carcinoma and its relationship with clincopathological data. Methods SP immunohistochemical technique was used to detect the expression of MTA1 and MMP-9 protein among 56 breast cancer samples. Results The positive rates of MTA1 and MMP-9 proteins were 69.6% （ 39/56 ） and 73.2% （ 41/56 ） , respectively. The high expression of MTA1 and MMP-9 proteins was significantly related with degrees of differentiation,clinical phases and lymph node metastasis （ P 〈 0.05 ）. Conclusion The expression of MTA1 and MMP-9 can be taken as the biological marker of prognosis and postoperative comprehensive treatment of breast carcinoma.
作者 李孟圈 王家祥 苏静 鲍俊涛 李靖若
机构地区 郑州大学第一附属医院乳腺外科
出处 《中国综合临床》 北大核心 2008年第4期318-320,共3页 Clinical Medicine of China
基金 河南省卫生厅基金资助项目（20060038）
关键词 乳腺癌 肿瘤转移相关基因 基质金属蛋白酶-9 Breast cancer Metastasis-associated gene 1 MMP-9
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Yu Q,Stamenkovie I. Cell surface-localized matrix metalloproteinase- proteolytieally activates TGF-beta and promotes tumor invasion and angiogenesis[ J]. Genes Dev,2000,14(2) :163-176.
  • 2Pencil SD,Toh Y, Nicolson GL. Candidate metastasis-associated genes of the rat 13762NF mammary adenoearcinoma [ J ]. Breast Caneer Res Treat,1993,25(2) :165-174.
  • 3Nawa A ,Nishimori K, Lin P, ct al. Tumor metastasis-associated human MTA1 gene:its deduced protein sequence,location,and association with breast cancer cell proliferation using antiseuscphosphorothioateoligonuclcotidcs[ J]. J Cell Biochcm,2000,79(2) :202-212.
  • 4Sasaki H, Moriyama S, Nakashima Y, et al. Expression of the MTA1 mRNA in advanced lung cancer [ J ]. Lung Cancer, 2002,35 (2) :149-154.
  • 5Toh Y, Ohga T, Endo K, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histoneH4 in esophageal squamous cell carcinomas [ J].Int J Cancer, 2004,110(3) :362-367.
  • 6Hamatsu T, Rikimaru T, Yamashita Y, et al. The role of MTA1 geneexpression in human hepatocellular carcinoma [ J ]. Oncol Rep, 2003,10 (3) :599-604.
  • 7Hofer MD,Kuefer R,Varambally S,et al. The role of metastasis-associated protein 1 in prostate cancer progression [ J]. Cancer Res, 2004,64 (3) :825-829.
  • 8Reimers N ,Zafrakas K, Assmann V, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatie and primary mammary carcinoma cells [ J ]. Clin Cancer Res, 2004,10 ( 10 ) : 3422-3428.
  • 9李林瑞,焦丽,李建辉,曹伟,王宏.乳腺癌患者手术前后外周血基质金属蛋白酶和基质金属蛋白酶组织抑制剂的动态监测[J].中国基层医药,2007,14(9):1411-1412. 被引量：1
  • 10Mira E,Lacalle RA,Buesa JM,et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface[ J]. J Cell Sci ,2004,117 ( Pt 9 ) : 1847- 1857.

二级参考文献11

  • 1Fan SQ, Wei QY, Li MR, et al. Expression and cfinieal significance of MMP-2, MMP-9, TIMP- 1, and TIMP-2 in breast carcinoma. Ai Zheng, 2003,22 (9) : 968-973.
  • 2Tutton MG, George ML, Eccles SA, et al. Use of plasma MMP-2 and MMP-9 levels as a surrogate for turnout expression in colorectal cancer patients, Int J Cancer,2003,107(4) :541-550.
  • 3Guan KP,Ye HY,Yan Z, et ah Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology, 2003, 61 ( 4 ) : 719-723.
  • 4Ylisirni S, Hoyhtya M, Makitaro R, et ah Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase(TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res,2001,7(6) :1633-1637.
  • 5Mannello F, Gazzanelli G, Tissue inhibitors of metalloproteinases and programmed Cell death : Conundrums, controversies and potential implictions. Apoptosis, 2001,6(6) :479-482.
  • 6Nelson AR, Fringleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 2000,18(5) : 1135-1149.
  • 7Balduyck M, Zerimech F, Gouyer V, et al. Specific expression of matrix metalloproteinases 1,3,9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis, 2000, 18(2):171- 178.
  • 8Susskind H, Hymowitz MH, Lau YH, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys,2003,56(4) : 1161-1169.
  • 9Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med,2006,10(2) :499-510.
  • 10Giannelli G, Erriquez R, Fransvea E, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer, 2004,109 (5) :782-785.

同被引文献11

引证文献1

二级引证文献9

中国综合临床
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部